S&P 500   3,847.91 (+0.17%)
DOW   30,918.37 (-0.25%)
QQQ   327.26 (+0.57%)
AAPL   142.63 (+2.56%)
MSFT   228.53 (+1.14%)
FB   276.82 (+0.85%)
GOOGL   1,868.95 (-1.25%)
AMZN   3,303.50 (+0.34%)
TSLA   868.47 (+2.58%)
NVDA   546.29 (-0.40%)
BABA   260.48 (+0.72%)
CGC   32.79 (-2.99%)
GE   10.96 (-1.35%)
MU   81.00 (-1.56%)
AMD   94.28 (+1.61%)
NIO   60.15 (-2.91%)
T   29.02 (+0.31%)
F   11.07 (-3.91%)
ACB   10.21 (-4.13%)
BA   202.90 (-1.43%)
DIS   170.75 (-1.17%)
NFLX   554.45 (-1.90%)
GILD   67.42 (+0.72%)
S&P 500   3,847.91 (+0.17%)
DOW   30,918.37 (-0.25%)
QQQ   327.26 (+0.57%)
AAPL   142.63 (+2.56%)
MSFT   228.53 (+1.14%)
FB   276.82 (+0.85%)
GOOGL   1,868.95 (-1.25%)
AMZN   3,303.50 (+0.34%)
TSLA   868.47 (+2.58%)
NVDA   546.29 (-0.40%)
BABA   260.48 (+0.72%)
CGC   32.79 (-2.99%)
GE   10.96 (-1.35%)
MU   81.00 (-1.56%)
AMD   94.28 (+1.61%)
NIO   60.15 (-2.91%)
T   29.02 (+0.31%)
F   11.07 (-3.91%)
ACB   10.21 (-4.13%)
BA   202.90 (-1.43%)
DIS   170.75 (-1.17%)
NFLX   554.45 (-1.90%)
GILD   67.42 (+0.72%)
S&P 500   3,847.91 (+0.17%)
DOW   30,918.37 (-0.25%)
QQQ   327.26 (+0.57%)
AAPL   142.63 (+2.56%)
MSFT   228.53 (+1.14%)
FB   276.82 (+0.85%)
GOOGL   1,868.95 (-1.25%)
AMZN   3,303.50 (+0.34%)
TSLA   868.47 (+2.58%)
NVDA   546.29 (-0.40%)
BABA   260.48 (+0.72%)
CGC   32.79 (-2.99%)
GE   10.96 (-1.35%)
MU   81.00 (-1.56%)
AMD   94.28 (+1.61%)
NIO   60.15 (-2.91%)
T   29.02 (+0.31%)
F   11.07 (-3.91%)
ACB   10.21 (-4.13%)
BA   202.90 (-1.43%)
DIS   170.75 (-1.17%)
NFLX   554.45 (-1.90%)
GILD   67.42 (+0.72%)
S&P 500   3,847.91 (+0.17%)
DOW   30,918.37 (-0.25%)
QQQ   327.26 (+0.57%)
AAPL   142.63 (+2.56%)
MSFT   228.53 (+1.14%)
FB   276.82 (+0.85%)
GOOGL   1,868.95 (-1.25%)
AMZN   3,303.50 (+0.34%)
TSLA   868.47 (+2.58%)
NVDA   546.29 (-0.40%)
BABA   260.48 (+0.72%)
CGC   32.79 (-2.99%)
GE   10.96 (-1.35%)
MU   81.00 (-1.56%)
AMD   94.28 (+1.61%)
NIO   60.15 (-2.91%)
T   29.02 (+0.31%)
F   11.07 (-3.91%)
ACB   10.21 (-4.13%)
BA   202.90 (-1.43%)
DIS   170.75 (-1.17%)
NFLX   554.45 (-1.90%)
GILD   67.42 (+0.72%)
Log in
NASDAQ:TBIO

Translate Bio Stock Forecast, Price & News

$24.78
+1.75 (+7.60 %)
(As of 01/25/2021 02:03 PM ET)
Add
Compare
Today's Range
$23.32
Now: $24.78▼
$25.12
50-Day Range
$18.43
MA: $22.31▼
$27.56
52-Week Range
$6.80
Now: $24.78▼
$28.09
Volume33,345 shs
Average Volume867,943 shs
Market Capitalization$1.84 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.96
Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. was founded in 2011 and is headquartered in Lexington, Massachusetts.

MarketRank™

Overall MarketRank™

1.37 out of 5 stars

Medical Sector

579th out of 1,922 stocks

Biological Products, Except Diagnostic Industry

79th out of 177 stocks

Analyst Opinion: 3.5Community Rank: 1.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TBIO
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.translate.bio
Phone617-945-7361
Employees93
Year FoundedN/A

Debt

Debt-to-Equity RatioN/A
Current Ratio5.73
Quick Ratio5.73

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$7.80 million
Price / Sales236.12
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.56 per share
Price / Book9.68

Profitability

EPS (Most Recent Fiscal Year)($1.84)
Net Income$-113,290,000.00
Net Margins-70.38%
Return on Equity-27.54%
Return on Assets-12.82%

Miscellaneous

Outstanding Shares74,322,000
Market Cap$1.84 billion
Next Earnings Date3/11/2021 (Estimated)
OptionableNot Optionable
$24.78
+1.75 (+7.60 %)
(As of 01/25/2021 02:03 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for TBIO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Translate Bio (NASDAQ:TBIO) Frequently Asked Questions

How has Translate Bio's stock been impacted by Coronavirus (COVID-19)?

Translate Bio's stock was trading at $7.43 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, TBIO shares have increased by 232.4% and is now trading at $24.70.
View which stocks have been most impacted by COVID-19.

Is Translate Bio a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Translate Bio in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Translate Bio stock.
View analyst ratings for Translate Bio or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Translate Bio?

Wall Street analysts have given Translate Bio a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Translate Bio wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Craig J. Tuttle's approval rating as Translate Bio's CEO?

13 employees have rated Translate Bio CEO Craig J. Tuttle on Glassdoor.com. Craig J. Tuttle has an approval rating of 5% among Translate Bio's employees. This puts Craig J. Tuttle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

When is Translate Bio's next earnings date?

Translate Bio is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Translate Bio.

How were Translate Bio's earnings last quarter?

Translate Bio, Inc. (NASDAQ:TBIO) released its quarterly earnings data on Thursday, November, 5th. The company reported $0.23 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.20 by $0.03. The business had revenue of $66.45 million for the quarter, compared to analyst estimates of $58.97 million. Translate Bio had a negative trailing twelve-month return on equity of 27.54% and a negative net margin of 70.38%.
View Translate Bio's earnings history.

What price target have analysts set for TBIO?

8 brokerages have issued 12-month price objectives for Translate Bio's stock. Their forecasts range from $19.00 to $40.00. On average, they expect Translate Bio's stock price to reach $32.14 in the next twelve months. This suggests a possible upside of 30.1% from the stock's current price.
View analysts' price targets for Translate Bio or view Wall Street analyst' top-rated stocks.

Who are some of Translate Bio's key competitors?

Some companies that are related to Translate Bio include Halozyme Therapeutics (HALO), Beam Therapeutics (BEAM), Relay Therapeutics (RLAY), Vir Biotechnology (VIR), China Biologic Products (CBPO), Allogene Therapeutics (ALLO), SpringWorks Therapeutics (SWTX), Immunovant (IMVT), Editas Medicine (EDIT), Ablynx (ABLYF), Kymera Therapeutics (KYMR), NanoString Technologies (NSTG), bluebird bio (BLUE), Revolution Medicines (RVMD) and AlloVir (ALVR).
View all of TBIO's competitors.

What other stocks do shareholders of Translate Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Translate Bio investors own include Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Novavax (NVAX), Pfizer (PFE), Moderna (MRNA), Johnson & Johnson (JNJ), Sorrento Therapeutics (SRNE), Vaxart (VXRT) and VBI Vaccines (vbiv).

Who are Translate Bio's key executives?

Translate Bio's management team includes the following people:
  • Mr. Ronald C. Renaud Jr., Pres, CEO & Director (Age 51, Pay $756.15k)
  • Mr. John R. Schroer C.F.A., CFA, CFO & Treasurer (Age 55, Pay $540k)
  • Dr. Richard Wooster, Chief Scientific Officer (Age 55, Pay $433.55k)
  • Mr. Paul D. Burgess J.D., Chief Legal Officer, COO & Sec. (Age 46)
  • Mr. Frank DeRosa, Chief Technology Officer
  • Ms. Teri Babine Dahlman, VP of Corp. Communications & Investor Relations
  • Ms. Paula A. Cloghessy, Chief People Officer (Age 49)
  • Mr. Brian Fenton M.S., MBA, Chief Bus. Officer (Age 52)
  • Dr. Ann Barbier M.D., Ph.D., Chief Medical Officer (Age 56)
  • Mr. Robert D. Prentiss, VP & Corp. Controller (Age 49)

When did Translate Bio IPO?

(TBIO) raised $100 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 7,700,000 shares at $12.00-$14.00 per share. Citigroup, Leerink Partners and Evercore ISI acted as the underwriters for the IPO.

What is Translate Bio's stock symbol?

Translate Bio trades on the NASDAQ under the ticker symbol "TBIO."

Who are Translate Bio's major shareholders?

Translate Bio's stock is owned by a number of retail and institutional investors. Top institutional investors include Strs Ohio (0.05%), McGuire Investment Group LLC (0.03%), Global Retirement Partners LLC (0.03%) and Pacer Advisors Inc. (0.00%). Company insiders that own Translate Bio stock include Baupost Group Llc/Ma, Human Genetic Therapies Shire and Jean Francois Formela.
View institutional ownership trends for Translate Bio.

Which major investors are selling Translate Bio stock?

TBIO stock was sold by a variety of institutional investors in the last quarter, including Global Retirement Partners LLC. Company insiders that have sold Translate Bio company stock in the last year include Human Genetic Therapies Shire, and Jean Francois Formela.
View insider buying and selling activity for Translate Bio or view top insider-selling stocks.

Which major investors are buying Translate Bio stock?

TBIO stock was bought by a variety of institutional investors in the last quarter, including Strs Ohio, McGuire Investment Group LLC, and Pacer Advisors Inc..
View insider buying and selling activity for Translate Bio or or view top insider-buying stocks.

How do I buy shares of Translate Bio?

Shares of TBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Translate Bio's stock price today?

One share of TBIO stock can currently be purchased for approximately $24.70.

How big of a company is Translate Bio?

Translate Bio has a market capitalization of $1.84 billion and generates $7.80 million in revenue each year. The company earns $-113,290,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis. Translate Bio employs 93 workers across the globe.

What is Translate Bio's official website?

The official website for Translate Bio is www.translate.bio.

How can I contact Translate Bio?

Translate Bio's mailing address is 29 HARTWELL AVENUE, LEXINGTON MA, 02421. The company can be reached via phone at 617-945-7361.

This page was last updated on 1/25/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.